Summary
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
History
I-Mab Biopharma was founded in June 2016. With its fully-integrated platform of drug development capabilities – including target identification and validation, early- to late-stage clinical development, regulatory filings and commercialization – I-Mab Biopharma creates value for patients and shareholders by advancing a robust pipeline of innovative new medicines.
Mission
We are dedicated to discovering, developing and delivering novel innovative medicine for immunological or oncological diseases, leveraging our fully-integrated platform of drug development capabilities and through our dedicated and experienced team.
Vision
We aspire to be the leading innovative biopharmaceutical company in China, driving patient access to new treatments in our therapeutic areas of focus and generating superior returns for shareholders.
Key Team
Dr. Weiming Tang Ph.D. (Exec. VP of Global Bus. Devel. & Chief Bus. Officer)
Dr. Fernando J. Salle´s Ph.D. (Sr. VP and Head of U.S. & EU Bus. Devel.)
Mr. Ivan Yifei Zhu (Chief Commercial Officer)
Mr. Richard L. Yeh M.B.A. (Interim CFO, COO & Director)
Mr. Tianyi Zhang (VP of Investor Relations)
Mr. Cheng Li (Chief Legal Officer)
Ms. Gigi Qi Feng (Chief Communications Officer)
Recognition and Awards
I-Mab has been recognized as one of 2019's Top 20 Startups in China by Forbes, as well as being named to the 2018 Forbes China Up-and-Coming Innovative List and the 2019 Forbes China Emerging Unicorn List. In addition, I-Mab Biopharma was the recipient of the 2018 Red Herring Top 100 Asia Award.
References
China 